Modern Rheumatology最新文献_第3页

Prevalence of social frailty in patients with rheumatoid arthritis: data from a multicenter observational study (T-FLAG study). 类风湿性关节炎患者社会脆弱性的普遍性：一项多中心观察研究（T-FLAG 研究）的数据。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-08-23 DOI: 10.1093/mr/roae078

Mochihito Suzuki, Shuji Asai, Yoshifumi Ohashi, Yasumori Sobue, Hisato Ishikawa, Kenya Terabe, Ryo Sato, Hironobu Kosugiyama, Junya Hasegawa, Yusuke Ohno, Takaya Sugiura, Shiro Imagama

{"title":"Prevalence of social frailty in patients with rheumatoid arthritis: data from a multicenter observational study (T-FLAG study).","authors":"Mochihito Suzuki, Shuji Asai, Yoshifumi Ohashi, Yasumori Sobue, Hisato Ishikawa, Kenya Terabe, Ryo Sato, Hironobu Kosugiyama, Junya Hasegawa, Yusuke Ohno, Takaya Sugiura, Shiro Imagama","doi":"10.1093/mr/roae078","DOIUrl":"https://doi.org/10.1093/mr/roae078","url":null,"abstract":"Background: This study aimed to investigate the prevalence of social frailty and associated factors.Methods: A total of 655 consecutive patients who were able to complete the Kihon Checklist (KCL) and the Questionnaire on Social Frailty between June and August 2022 were enrolled. Social frailty was assessed using the Makizako Social Frailty Index. Patient characteristics were analyzed by analysis of variance. Factors associated with social frailty were analyzed using multivariate logistic analysis. Spearman's rank correlation coefficients were used to examine correlations between each KCL domain and social frailty.Results: Mean age was 68 years, and disease duration was 12 years; 73% of patients were female. Social frailty was present in 30.8% of patients, with 36.5% classified as social pre-frailty. Multivariate analysis revealed age and HAQ-DI to be independent factors associated with social frailty. The proportion of social frailty increased with increasing age and worsening HAQ-DI scores. The KCL domain \"Isolation\" was the most strongly associated with social frailty (r = 0.601, P < 0.001), with higher scores associated with a higher proportion of social frailty.Conclusions: Social frailty in RA patients is associated with age and physical impairment (HAQ-DI). Moreover, the KCL domain \"Isolation\" was strongly associated with social frailty.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142036370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nationwide epidemiological survey of juvenile idiopathic arthritis during transition to young adulthood in Japan using the National Database of Designated Incurable Diseases of Japan. 利用日本国家指定不治之症数据库，对日本幼年特发性关节炎向青年期过渡的全国流行病学调查。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-08-22 DOI: 10.1093/mr/roae076

Yuzaburo Inoue, Ryoko Sakai, Eisuke Inoue, Kanako Mitsunaga, Masaki Shimizu, Takahiko Sugihara, Masakazu Matsushita, Ken Yamaji, Masaaki Mori, Naoki Shimojo, Takako Miyamae

{"title":"Nationwide epidemiological survey of juvenile idiopathic arthritis during transition to young adulthood in Japan using the National Database of Designated Incurable Diseases of Japan.","authors":"Yuzaburo Inoue, Ryoko Sakai, Eisuke Inoue, Kanako Mitsunaga, Masaki Shimizu, Takahiko Sugihara, Masakazu Matsushita, Ken Yamaji, Masaaki Mori, Naoki Shimojo, Takako Miyamae","doi":"10.1093/mr/roae076","DOIUrl":"https://doi.org/10.1093/mr/roae076","url":null,"abstract":"Objectives We aimed to assess the unmet medical needs of young adult patients with juvenile idiopathic arthritis by evaluating real-world treatment data. Methods We analyzed data on juvenile idiopathic arthritis in the 20-29 age group from the National Database of Designated Incurable Diseases of Japan, which records severe cases or those requiring high-cost medical care registered between April 2018 and March 2020. Results Overall, 322 patients with juvenile idiopathic arthritis transitioning to adulthood were included. A high frequency of methotrexate use was observed among all juvenile idiopathic arthritis subtypes. The frequency of methotrexate use at registration was significantly higher in patients with rheumatoid factor-positive polyarthritis and those with oligoarthritis or polyarthritis than in those with systemic arthritis. The historical use percentage of any biological disease-modifying antirheumatic drug was ≥85% for all juvenile idiopathic arthritis subtypes. The proportion of patients with ≥2 biological disease-modifying antirheumatic drug prescriptions was significantly higher in patients with rheumatoid factor-positive polyarthritis than in those with systemic arthritis. Conclusions High-cost drugs were necessary for many patients with juvenile idiopathic arthritis transitioning to young adulthood and registered in the database. Further studies on the medical interventions and support for these patients are needed.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142036368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Perspective on the Clinical and Laboratory Characteristics of Rheumatoid Pleural Effusion: A 29-Case Series. 类风湿胸腔积液临床和实验室特征的新视角：29例系列病例。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-08-22 DOI: 10.1093/mr/roae082

Saki Sada Minoda, Ryuichi Minoda Sada, Hiroyuki Akebo, Yukio Tsugihashi, Kazuhiro Hatta

{"title":"New Perspective on the Clinical and Laboratory Characteristics of Rheumatoid Pleural Effusion: A 29-Case Series.","authors":"Saki Sada Minoda, Ryuichi Minoda Sada, Hiroyuki Akebo, Yukio Tsugihashi, Kazuhiro Hatta","doi":"10.1093/mr/roae082","DOIUrl":"https://doi.org/10.1093/mr/roae082","url":null,"abstract":"Objective Rheumatoid pleural effusion (RPE) usually occurs in middle-aged men. Pleural fluid analyses have revealed high lactate dehydrogenase (LDH) levels and low pH and glucose levels in RPE. We aimed to investigate the clinical and laboratory features of patients with RPE since the beginning of the 21st century. Methods Medical records of patients with RPE were reviewed between May 2006 and October 2021. The patients were divided into <60-year (younger) and ≥60-year (older) groups. Results The younger group comprised 6 patients (median age 53.5 years, female 33%) and older group comprised 23 patients (median age 76 years, female 52.2%). Compared to the younger group, the older group had fewer cases of fever (83.3% vs. 18.2%, p = 0.007) and chest pain (66.7% vs. 8.7%, p = 0.008). In pleural fluid analysis, the older group presented higher pH (p = 0.004) and lower LDH levels (p = 0.044). Seven patients died during the follow-up period. Conclusion Most patients with RPE were over 60 years of age, and approximately half of them were female. The pleural fluid analysis showed milder inflammation in older patients than in middle-aged patients. The mortality rate of patients with RPE was distinctly higher than that previously reported.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142036369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delayed global standardization and prefectural disparities in systematic lupus erythematosus treatment in Japan: a nationwide study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. 日本系统性红斑狼疮治疗的全球标准化延迟和都道府县差异：利用日本全国健康保险索赔和特定健康检查数据库进行的全国性研究。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-08-21 DOI: 10.1093/mr/roae072

Naoto Yokogawa, Ryoko Sakai, Masakazu Matsushita, Masaki Shimizu, Yuzaburo Inoue, Eisuke Inoue, Ken Yamaji, Masaaki Mori, Takako Miyamae

{"title":"Delayed global standardization and prefectural disparities in systematic lupus erythematosus treatment in Japan: a nationwide study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.","authors":"Naoto Yokogawa, Ryoko Sakai, Masakazu Matsushita, Masaki Shimizu, Yuzaburo Inoue, Eisuke Inoue, Ken Yamaji, Masaaki Mori, Takako Miyamae","doi":"10.1093/mr/roae072","DOIUrl":"https://doi.org/10.1093/mr/roae072","url":null,"abstract":"Objectives: To evaluate the status of the global standardization of, and prefectural differences in, systematic lupus erythematosus (SLE) treatments in Japan.Methods: The Japanese National Database of Health Insurance Claims and Specific Health Checkups (NDB Japan) was used. A patient with SLE was defined as having a disease with ICD10 code M321 or M329 between April 2019 and March 2020, for which oral corticosteroids (OCS), immunosuppressive agents or biologic agents were prescribed at least once during a given month. SLE treatments were evaluated by treatment center type and prefecture.Results: In total, 74,277 patients met the definition of SLE. The SLE prevalence was 60 per 100,000 (range: 47 - 102 per 100,000 by prefecture). Nationwide, 79.4% of the patients (range: 52.1% - 93.3% by prefecture) visited a specialized treatment center (STC); 37.4% (range: 26.4% - 51.3% by prefecture) received only OCS, with fewer of these patients visiting a STC than a non-STC (34.8% and 49.7%, p<0.001); and 21.4% (range: 10.7% - 35.0%) received HCQ, with more of these patients visiting a STC than a non-STC (23.0% and 13.5%; p<0.001).Conclusions: NDB Japan demonstrated delayed global standardization of, and prefectural disparity in, SLE treatments in Japan.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142017987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The dietary acid load is associated with disease severity in psoriatic arthritis. 膳食酸负荷与银屑病关节炎(PsA)的疾病严重程度相关。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-08-20 DOI: 10.1093/mr/road107

Sümeyra Öteleş, Gizem Ayan, Mustafa Ekici, Edibe Ünal, Pelin Bilgiç, Umut Kalyoncu

{"title":"The dietary acid load is associated with disease severity in psoriatic arthritis.","authors":"Sümeyra Öteleş, Gizem Ayan, Mustafa Ekici, Edibe Ünal, Pelin Bilgiç, Umut Kalyoncu","doi":"10.1093/mr/road107","DOIUrl":"10.1093/mr/road107","url":null,"abstract":"Objectives: An acidogenic diet, by disrupting the blood pH equilibrium, can contribute to metabolic acidosis and lead to inflammation. Therefore, we hypothesized that dietary acid load (DAL) increases disease activity and inflammation in psoriatic arthritis (PsA) patients.Methods: This study was conducted with 58 obese/overweight patients, aged 20-65 years. Dietary intake was assessed using a 3-consecutive-day 24-hour recall. The DAL was evaluated through the PRAL (potential renal acid load) and NEAP (net endogenous acid production) and divided into the low and high groups by their median values. The disease activity assessments, anthropometric measurements, dietary data, and blood parameters of patients were recorded and compared at the low and high DAL groups.Results: We observed that patients in the high NEAP and PRAL groups had worse PsA pattern scores (P < 0.05). Also, PRAL and NEAP scores were positively associated with Disease Activity Index for Psoriatic Arthritis, Health Assessment Questionnaire, and Psoriatic Arthritis Impact of Disease-12 (PSAID-12) scores. After adjusting age, sex, smoking, and body mass index, 1 mEq increase in PRAL and NEAP was associated with an elevation of Disease Activity Index for Psoriatic Arthritis (0.506 and 0.486 points, respectively).Conclusions: These results showed a close relationship between DAL and PsA symptoms. An acidogenic diet may negatively affect PsA prognosis. Healthy eating recommendations should be part of the management of the disease.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89718854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Examination of prognostic factors in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. 抗黑素瘤分化相关基因 5 抗体阳性皮肌炎预后因素研究

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-08-20 DOI: 10.1093/mr/roae007

Suzuna Sugi, Masaki Tominaga, Shinjiro Kaieda, Kiminori Fujimoto, Tomonori Chikasue, Takuma Koga, Yuri Hasuo, Erina Iwanaga, Kenta Murotani, Jamie Kristen T Lim, Hiroaki Ida, Tomotaka Kawayama, Tomoaki Hoshino

{"title":"Examination of prognostic factors in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.","authors":"Suzuna Sugi, Masaki Tominaga, Shinjiro Kaieda, Kiminori Fujimoto, Tomonori Chikasue, Takuma Koga, Yuri Hasuo, Erina Iwanaga, Kenta Murotani, Jamie Kristen T Lim, Hiroaki Ida, Tomotaka Kawayama, Tomoaki Hoshino","doi":"10.1093/mr/roae007","DOIUrl":"10.1093/mr/roae007","url":null,"abstract":"Objective: This study investigated the prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5-DM).Methods: This study analysed 34 MDA5-DM cases (20 and 14 in the survival and death groups, respectively) encountered at Kurume University between 2008 and 2021. The clinical, physiological, and computed tomography findings, pulmonary function, and serological results were retrospectively evaluated for each MDA5-DM case during the first visit and throughout the next 12 weeks.Results: In the death group, the mean age of patients was higher (47.6 vs. 61.8 years), while the duration from symptom onset to consultation was shorter (110 vs. 34.9 days). During the first visit, the death group demonstrated a significantly higher serum C-reactive protein level (0.52 vs. 1.99) and a significantly lower albumin level (3.23 vs. 2.63) than the survival group; this persisted throughout the next 12 weeks. Poor prognosis was associated with C-reactive protein and albumin levels >0.19 mg/dl and <2.3 g/dl, respectively, 4 weeks after starting the treatment.Conclusion: Four weeks after starting the treatment, serum C-reactive protein and albumin levels of patients with MDA5-DM can be used to evaluate treatment response and predict prognosis.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139651161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between matrix metalloprotease-3 levels and radiographic progression in patients with rheumatoid arthritis: A post hoc analysis from a Japanese Phase 3 clinical trial of peficitinib (RAJ4). 基质金属蛋白酶-3水平与RA患者放射学进展之间的关系：来自日本培非替尼（RAJ4）3期临床试验的事后分析。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-08-20 DOI: 10.1093/mr/road102

Tsutomu Takeuchi, Yoshiya Tanaka, Yoshiaki Morita, Daisuke Kato, Yuichiro Kaneko, Wataru Terada

{"title":"Association between matrix metalloprotease-3 levels and radiographic progression in patients with rheumatoid arthritis: A post hoc analysis from a Japanese Phase 3 clinical trial of peficitinib (RAJ4).","authors":"Tsutomu Takeuchi, Yoshiya Tanaka, Yoshiaki Morita, Daisuke Kato, Yuichiro Kaneko, Wataru Terada","doi":"10.1093/mr/road102","DOIUrl":"10.1093/mr/road102","url":null,"abstract":"Objectives: The current study assesses the utility of matrix metalloprotease-3 (MMP-3) as a biomarker for joint damage in patients with rheumatoid arthritis receiving peficitinib.Methods: Rheumatoid arthritis patients with inadequate response to methotrexate were randomised to peficitinib 100 mg, peficitinib 150 mg, or placebo, combined with methotrexate, for 52 weeks; patients receiving placebo switched to peficitinib 100/150 mg at Week (W)12/28. This post hoc analysis investigated association between MMP-3 above/below upper limit of normal (ULN) at W12/28 and radiographic progression [modified total Sharp score (mTSS), joint space narrowing score, or erosion score >0.5] at W52 or swollen joint count 66 at W28, stratified by baseline glucocorticoid use and renal function.Results: MMP-3 levels decreased in both peficitinib-treated groups but more slowly in patients with baseline glucocorticoids and those with radiographic progression at W52. There was no clear correlation between MMP-3 change from baseline (CFB) at W12, CFB in mTSS, joint space narrowing score, or erosion score at W52, or CFB in swollen joint count 66 at W28. More patients with MMP-3 ≤ULN versus >ULN at W12 had radiographic non-progression at W52. MMP-3 normalisation at W12 was significantly associated with mTSS non-progression at W52.Conclusions: Normalisation of MMP-3 at W12 may be a predictor for subsequent non-progression of joint damage at W52.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71413085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in treatment for patients with late-onset rheumatoid arthritis in Japan: Data from the NinJa study. 日本晚发型类风湿关节炎患者的治疗趋势：来自 NinJa 研究的数据。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-08-20 DOI: 10.1093/mr/roae006

Toshihiro Matsui, Tomoya Yoshida, Takahiro Nishino, Shigeru Yoshizawa, Tetsuji Sawada, Shigeto Tohma

{"title":"Trends in treatment for patients with late-onset rheumatoid arthritis in Japan: Data from the NinJa study.","authors":"Toshihiro Matsui, Tomoya Yoshida, Takahiro Nishino, Shigeru Yoshizawa, Tetsuji Sawada, Shigeto Tohma","doi":"10.1093/mr/roae006","DOIUrl":"10.1093/mr/roae006","url":null,"abstract":"Objectives: Our objective was to investigate trends in the treatment of patients with late-onset rheumatoid arthritis (LORA) using data from the National Database of Rheumatic Diseases in Japan (NinJa).Methods: Patients registered in the National Database of Rheumatic Diseases in Japan were classified according to the disease onset: at <65 years (young-onset rheumatoid arthritis); at 65-74 years (early LORA); and at ≥75 years (late LORA). Chronological changes in the treatment and disease activity were compared.Results: A total of 7178, 13,171, 15,295, and 15,943 patients were evaluated in 2010, 2013, 2016, and 2019, respectively. In all groups, the use of methotrexate gradually decreased, whereas that of biological/targeted synthetic disease-modifying antirheumatic drugs (DMARDs) increased; the use of tumor necrosis factor inhibitors decreased, whereas that of non-tumor necrosis factor inhibitors increased. LORA was characterized by more single DMARD use and less methotrexate and biological/targeted synthetic DMARD use. Tumor necrosis factor inhibitors and interleukin-6 inhibitors were used less frequently, whereas abatacept was utilized more frequently in late versus early LORA. Conventional synthetic DMARD (excluding methotrexate) and glucocorticoid use was higher in late versus early LORA.Conclusions: This analysis revealed chronological changes in the treatment of LORA in Japan. Differences between early and late LORA suggest that patients are not a homogeneous population.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139521331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in prevalence, treatment use, and disease burden in patients with eosinophilic granulomatosis with polyangiitis in Japan: Real-world database analysis. 日本嗜酸性肉芽肿伴多血管炎患者的患病率、治疗使用和疾病负担趋势：真实世界数据库分析。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-08-20 DOI: 10.1093/mr/road104

Ken-Ei Sada, Takeo Suzuki, Sandra Joksaite, Shinyoung Ju, John Logie, George Mu, Jeremiah Hwee, Hideaki Kunishige, Takeo Ishii, Amit Adlak, Harini Vadlamudi, Rafael Alfonso-Cristancho

{"title":"Trends in prevalence, treatment use, and disease burden in patients with eosinophilic granulomatosis with polyangiitis in Japan: Real-world database analysis.","authors":"Ken-Ei Sada, Takeo Suzuki, Sandra Joksaite, Shinyoung Ju, John Logie, George Mu, Jeremiah Hwee, Hideaki Kunishige, Takeo Ishii, Amit Adlak, Harini Vadlamudi, Rafael Alfonso-Cristancho","doi":"10.1093/mr/road104","DOIUrl":"10.1093/mr/road104","url":null,"abstract":"Objectives: We report the prevalence of eosinophilic granulomatosis with polyangiitis (EGPA) and describe oral corticosteroid (OCS) use and disease burden before and after the mepolizumab approval in 2018 for EGPA in Japan.Methods: Two retrospective studies (GSK IDs: 218083 and 218084) used two databases: (1) the JMDC insurer database (Japanese health insurer claims) was used to report annual EGPA prevalence and OCS use in mepolizumab-treated patients and (2) Medical Data Vision database was used to report annual treatment use, OCS dose, relapses, and healthcare resource utilization in patients with EGPA.Results: EGPA prevalence (95% confidence interval) increased from 4.2 (0.1, 23.4) in 2005 to 58.6 (53.2, 64.5) per 1,000,000 in 2020. Median OCS dose (mg/day) decreased from a range of 4.8-7.7 during 2010-2017 to 4.5-4.8 during 2018-2020 (lowest dose in 2020). The proportion of patients with prednisolone-equivalent daily OCS dose >10 mg decreased from 2017 (11.9%) to 2020 (10.3%), while the median dose halved. The proportion of patients with EGPA relapses (64.3% to 41.6%) and hospitalization (27.8% to 23.6%) decreased from 2010 to 2020.Conclusions: EGPA prevalence increased between 2005 and 2020. With the introduction of mepolizumab for EGPA in 2018, real-world OCS use, relapses, and healthcare resource utilization decreased.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71483664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: A post hoc analysis of a multicentre, open-label, randomised, parallel-group study. 地诺单抗与类风湿性关节炎患者血清细胞因子、趋化因子和骨相关因子的关系：一项多中心、开放标签、随机、平行组研究的事后分析。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-08-20 DOI: 10.1093/mr/roae002

Naoki Iwamoto, Shuntaro Sato, Kaori Furukawa, Toru Michitsuji, Kazuteru Shiraishi, Kounosuke Watanabe, Ko Chiba, Makoto Osaki, Atsushi Kawakami

{"title":"Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: A post hoc analysis of a multicentre, open-label, randomised, parallel-group study.","authors":"Naoki Iwamoto, Shuntaro Sato, Kaori Furukawa, Toru Michitsuji, Kazuteru Shiraishi, Kounosuke Watanabe, Ko Chiba, Makoto Osaki, Atsushi Kawakami","doi":"10.1093/mr/roae002","DOIUrl":"10.1093/mr/roae002","url":null,"abstract":"Objectives: To clarify changes in serum cytokines, chemokines, and bone-related factors during denosumab treatment in rheumatoid arthritis (RA) patients.Methods: This was a post hoc analysis of a multicentre, open-label, randomised, parallel-group study. Patients were randomly assigned to continue treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) plus receive treatment with denosumab (csDMARDs plus denosumab group) or to continue treatment with csDMARD therapy alone for 12 months. Serum biomarker levels were measured at baseline and at 6 and 12 months.Results: Baseline and 6-month data from the csDMARDs plus denosumab (n = 22) and csDMARD therapy alone (n = 22) groups were analysed. Statistically significant changes from baseline were seen: Dickkopf-related protein 1 decreased at 6 and 12 months (both groups); osteopontin decreased at 6 months in the csDMARDs plus denosumab group; osteopontin and soluble CD40 ligand increased at 6 and 12 months in the csDMARD therapy alone group; osteocalcin decreased at 6 and 12 months, epidermal growth factor decreased at 12 months, and macrophage-derived chemokine decreased at 6 months in the csDMARDs plus denosumab group; and interferon gamma-induced protein-10 increased at 12 months in the csDMARD therapy alone group.Conclusions: Denosumab may inhibit bone destruction by suppressing bone-related factors/chemokines.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139472754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0